News

Laurent Pharmaceuticals Starts Phase 3 Study with Once-a-Day Oral COVID-19 Antiviral Treatment Candidate in Hospitalized Moderate-to-Severe Patients

15 February 2022

Following the positive outcome of a meeting with the FDA, a first patient was recruited in the Phase 3 expansion of...

Read More

Laurent Pharmaceuticals extends COVID-19 Phase 2 study with oral antiviral LAU-7b that has showed 100% reduction in the risk of progression onto mechanical ventilation and death

15 December 2021

FDA allows Phase 2 study extension focusing on moderate-to-severe COVID-19 patients and grants Type B meeting to discuss eligibility to Emergency...

Read More

EVENTS

Laurent Pharmaceuticals presents data with LAU-7b in Idiopathic Pulmonary Fibrosis at the 2024 ATS International Conference, May 17-22, San Diego, CA, USA
Laurent Pharma to participate to BIO International Convention,  June 3-6 2024, San Diego, CA, USA

Laurent Pharma to participate to BIO International Convention, June 5-8, 2023, Boston, MA

Laurent Pharma to participate to BIO International Convention, June 13-16, 2022 – San Diego, CA
Laurent Pharma to participate to BIO-Europe Spring, March 28-31, 2022